3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Hepatocellular
27
Parkinson Disease 4, Autosomal Dominant Lewy Body
24
Neoplasms
14
Melanoma
9
Endometrial Neoplasms
8
Carcinoma, Renal Cell
7
Carcinoma, Non-Small-Cell Lung
7
Thyroid Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
6
Cholangiocarcinoma
6
Stomach Neoplasms
4
Recurrence
4
Carcinoma
4
Biliary Tract Neoplasms
4
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Lymphoma
3
Colorectal Neoplasms
3
Triple Negative Breast Neoplasms
2
Paraganglioma, Extra-Adrenal
2
Osteosarcoma
2
Neuroendocrine Tumors
2
Lung Neoplasms
2
Liver Neoplasms
2
Glioma
2
Esophageal Neoplasms
2
Carcinoma, Transitional Cell
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid cancer, Hurthle cell
1
Interventions
Gemcitabine
34
Cisplatin
21
Capecitabine
18
Oxaliplatin
15
Leucovorin
10
Fluorouracil
10
Irinotecan
8
Erlotinib Hydrochloride
7
pembrolizumab
5
Bevacizumab
5
Radiotherapy
4
Carboplatin
4
Albumin-Bound Paclitaxel
4
130-nm albumin-bound paclitaxel
4
Watchful Waiting
3
Taxes
3
Sorafenib
3
Platinum
3
Interleukin-12 Subunit p35
3
Immunohistochemistry
3
Docetaxel
3
1,2-diaminocyclohexaneplatinum II citrate
3
trifluridine tipiracil drug combination
2
tremelimumab
2
regorafenib
2
durvalumab
2
dehydroftorafur
2
Trastuzumab
2
Paclitaxel
2
N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Gallbladder Neoplasms
×
lenvatinib
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled